Simcere Pharmaceutical
2096 · HKEX
Public Market Listing
Live quotes, historical charts, and market capitalization for Simcere Pharmaceutical are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(9 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | ALK;ROS1Small molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | VEGFR2 (KDR/Flk-1) on vascular endothelial cellsProtein / enzyme therapeutic | Non-Small Cell Lung Cancer | |
| Phase 3 | PD-L1Monoclonal antibody | HIVNon-Small Cell Lung CancerChronic Hepatitis BEndometrial Cancer | |
| Phase 3 | NF-kB | Rheumatoid Arthritis | |
| Phase 3 | JAK1/2Small molecule | Atopic Dermatitis | |
| Phase 3 | IL-4R-alphaMonoclonal antibody | Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthma | |
| Phase 3 | JAK1Small molecule | Atopic DermatitisRheumatoid Arthritis | |
Pegylated Recombinant Human EndostatinNo recent activity | Phase 1 | Broad anti-angiogenic activityProtein / enzyme therapeutic | Non-Small Cell Lung Cancer |
| Phase 1 | GPRC5D x BCMA x CD3Multispecific antibody | Multiple Myeloma |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (4)
November 2026 (1)
What to watch
December 2026 (3)
What to watch
What to watch
What to watch
2027 (2)
2029 (1)
June 2029 (1)
What to watch
Regulatory and conference events
(9)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.1B | — | — | — | report ↗ |